Docetaxel-Based Combined Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Docetaxel-Based Combined Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Giorgio V. Scagliotti, Andrew T. Turrisi, III Oncologist 2003; 8: 361-374 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Offer a critical analysis of docetaxel radiotherapy clinical studies and provide background basic science support. Discuss dose/administration/timing information, as available, for docetaxel and radiotherapy and provide a foundation for clinical use and a platform for further research. Explain the potential benefit and outline the toxicities of the combination as used in international studies. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 1, 2003 Most Recent Review: Aug. 1, 2003* Most Recent Update: Aug. 1, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.